Caribou Biosciences, Inc. CRBU
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Caribou Biosciences, Inc. (CRBU) is a healthcare company listed in the US with a market value of about $39M. In the twelve months to September 30, 2026 it had revenue of $9M and net income of -$102M, a net margin of -1085.0%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -2% a year, a 5-year average ROIC of -44%.
About Caribou Biosciences
Caribou Biosciences is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $6M in 2019 to $11M in 2025, growth of about 11.6% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 54% over three years (dilution for shareholders). It spends 981% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9M | $11M | $10M | $34M | $14M | $10M | $12M | $6M |
| Net income | -$102M | -$148M | -$149M | -$102M | -$99M | -$67M | -$34M | -$23M |
| Free cash flow | -$93M | -$112M | -$143M | -$105M | -$97M | -$35M | -$34M | -$33M |
| EPS (diluted) | $-1.03 | $-1.59 | $-1.65 | $-1.38 | $-1.64 | $-2.11 | $-4.01 | $-2.80 |
| Net margin | -1085.0% | -1327.4% | -1491.9% | -296.1% | -717.8% | -697.3% | -277.6% | -404.8% |
| ROIC | — | -98.9% | -59.6% | -23.2% | -25.6% | -13.6% | — | -347.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Caribou Biosciences pay a dividend?
Not currently.
Is Caribou Biosciences a good stock to buy?
We do not give buy or sell advice. Caribou Biosciences scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.